Benzinga | Mar 11, 2021 07:36AM EST

Phio Pharmaceuticals To Present New Data On PD-1 Targeting INTASYL At The 2021 American Association For Cancer Research Annual Meeting

MARLBOROUGH, Mass., March 11, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL(tm)) therapeutic platform, today announced it will present new study data regarding the direct drug application of its product candidate, PH-762, at the AACR Annual Meeting 2021. The AACR 2021 meeting will be held in a virtual format over two weeks, April 10-15 and May 17-21.